BD ups earnings target with strong Q3 bottom-line
This article was originally published in Clinica
Executive Summary
A 2% drop in revenues did not stop BD from recording strong bottom-line growth of around 15% for the third fiscal quarter. The Franklin Lakes, New Jersey-based company posted sales of $1.8bn, aided by its diagnostics business which made $566m, a 2% increase compared to the same period last year.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals